Mriglobal

Mriglobal, doing business as Midwest Research Institute, is a Kansas City-based 501(c)(3) nonprofit research organization that delivers clinical-grade pharmaceutical manufacturing, preclinical testing, diagnostic services, and biodefense research and development to the federal government as a prime contractor (99% of recent awards). The organization operates as a large, unrestricted vendor competing in full-and-open procurement across health, defense, and homeland security missions, with no small-business set-asides and a geographically distributed footprint spanning headquarters facilities in Kansas City (225,000 square feet with 60,000 square feet of laboratory space), biorepository sites in North Kansas City (87,000 square feet), and subordinate operational laboratories in Potomac, Maryland; Frederick, Maryland; and Edison, New Jersey.

Mriglobal's federal customer concentration is heavily weighted toward health and biodefense agencies. The National Institute of Allergy and Infectious Diseases (NIAID) dominates by dollar value—18 awards generating $1.2 billion in combined potential value—followed by the Office of the Assistant Secretary for Preparedness and Response (17 awards, $515.3 million), the National Cancer Institute (27 awards, $272 million), the Centers for Disease Control and Prevention (30 awards, $163.7 million), and the National Institute on Drug Abuse (10 awards, $118 million). These five customer organizations account for approximately 3% of the combined potential value across Mriglobal's 943-award footprint, reflecting the vendor's highly concentrated customer base and the dollar weight of a small number of large indefinite delivery vehicles. The Environmental Protection Agency and Department of the Army account for the highest award counts (228 and 85 awards respectively) but carry substantially lower individual values, indicating a different portfolio segment from the health and biodefense mission base.

The vendor holds anchor positions on multiple large IDIQs and master contracts that structure the majority of its task-order work. The OASIS+ Unrestricted government-wide MAC (awarded December 2024) carries a multi-billion-dollar ceiling through 2029, though the source marks this as a placeholder value; Mriglobal's recent ordering activity against it reflects real health and biodefense task orders. NIAID's $364.6 million multiple-award Preclinical and Translational Vaccine Development contract (awarded December 2021, through November 2028) is one of the largest single vehicles, with task orders spanning product storage and shipping, safety studies, and CGMP manufacturing. The National Cancer Institute's $49.99 million single-award Centralized Chemopreventive Agent Repository contract (awarded July 2023, through June 2028) drives significant NCI task-order volume, as does the NIAID $146.3 million single-award Pre-Clinical Models of Infectious Diseases contract. Additional high-value IDIQs include NCATS Chemistry, Manufacturing and Controls ($49.7 million, awarded May 2024), the NINDS Drug Manufacturing and Formulation Program ($50 million, awarded May 2026), and CDC's Diagnostic Testing IDIQ ($148 million, awarded September 2025). The vendor also sits on NCATS Safety Evaluation and Toxicology Studies ($48.6 million, awarded June 2024), ASPR Biological Animal Model and MCM Development ($100 million, awarded September 2022), and ASPR Chemical Threat Animal Models ($45 million, awarded July 2022). The NIDA Analytical Services Center for Medications Development IDIQ (awarded July 2026, $5 million ceiling) and NIAID Diagnostics Pre-Clinical Services ($24 million, awarded June 2023) round out the primary health-mission vehicles. Across SCI-reportable contracts, Mriglobal self-performs approximately 98% of contractor hours, indicating a primarily integrated delivery model with minimal subcontractor reliance.

Recent task-order activity illustrates capability depth across pharmaceutical manufacturing, diagnostics, biodefense, and medical countermeasures. Representative examples include a $97.999 million Joint Program Executive Office for CBRN Defense delivery order (awarded July 2024, through July 2029) for RDT&E supporting chemical, biological, radiological, and nuclear defense with named major subcontractors including Smiths Detection Inc., National Strategic Research Institute, Gentex Corporation, and Mesh Inc.; a $26.9 million National Cancer Institute delivery order (awarded July 2023, through June 2028) for centralized chemopreventive agent repository and chemistry support; a $21.88 million NIAID Mycobacterium tuberculosis Quality Assessment Program definitive contract (awarded November 2023, through November 2030) supporting proficiency testing, diagnostic validation, and quality control material distribution, with subcontractors including Johns Hopkins University and Bio-Rad Laboratories; a $13.813 million Environmental Protection Agency Portable High Throughput Integrated Laboratory Identification Systems (PHILIS) Platform Modernization 2.0 definitive contract (awarded January 2025, through January 2027) for mobile laboratory system upgrades with subcontractors Craftsmen Industries, Hemco Corporation, and specialty equipment suppliers; and a $3.46 million National Cancer Institute Epstein-Barr virus vaccine manufacture delivery order (awarded September 2025, through September 2027). The vendor also holds an $8.362 million Office of the Assistant Secretary for Preparedness and Response biocontainment unit design, fabrication, and delivery contract (awarded September 2023, through March 2025) and a $6.357 million Department of Homeland Security Countering Weapons of Mass Destruction Agnostic Threat Detection System RDT&E contract (awarded September 2023, through September 2027).

Activity has been stable across recent fiscal years—13 awards in 2022 rising to 23 in 2024—with 22 awards (combined potential value $175.1 million) reaching ultimate completion within the next twenty-four months and therefore facing recompete. In its role as subcontractor, Mriglobal performs technical support on DARPA research programs (The Charles Stark Draper Laboratory), vaccine reproducibility studies (BioFire Defense LLC), and proficiency testing services (Association of Public Health Laboratories grant sub-award). SCI-reported invoicing has grown year over year from $15 million in FY2022 (34.3 FTEs) to $29.7 million in FY2025 (50.1 FTEs), with government-paid rates ranging from $112/hr at the tenth percentile to $865/hr at the ninety-percent mark, reflecting a mix of entry-level technical labor and senior scientific expertise. The median SCI-reported hourly rate is $247/hr. Federal grants from HUD's Economic Development Initiative and HRSA Bureau of Primary Health Care support biorepository resiliency upgrades ($2023–2026 construction project) and headquarters life sciences capability expansion ($2022–2025 laboratory equipment project), totaling congressional directed spending focused on facility modernization and workforce development in the Kansas City region.